ReachRxResearch
Home
Research
Sign Up
Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower‐risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo‐controlled trial
Back to Research Hub
  1. Home
  2. Research Hub
  3. Oral vitamin C supplementation in patien…

Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower‐risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo‐controlled trial

Cancer·September 21Open Access
OncologyLimited evidenceChronic Myelomonocytic LeukemiaClonal Cytopenia Of Undetermined SignificanceMyelodysplastic SyndromesRandomized Controlled TrialVitamin SupplementOlder AdultAscorbic Acid

Summary

View source

What was studied

The EVITA trial evaluated oral vitamin C (1000 mg/day for 12 months) vs. placebo in 109 adults with clonal cytopenia of undetermined significance (CCUS) or lower-risk myeloid malignancies (MDS, CMML 0/1) not on anticancer therapy, with primary endpoint of clonal growth rate and follow-up through September 2023.

Key findings

The primary endpoint—median clonal growth rate—did not differ between groups (between-group difference −0.016; 95% CI, −0.096 to 0.064; p = .70). However, fewer serious adverse events occurred in the vitamin C arm (33% vs. 57%), inflammatory cytokines (IL-6, IL-10, CXCL10, M-CSF, G-CSF) rose less in the vitamin C group, and in exploratory analyses overall survival was significantly longer with vitamin C (HR 0.35; 95% CI, 0.17–0.71; p = .0025; median OS not reached vs. 42.2 months with placebo).

Study limitations

No formal sample size calculation was performed, leaving the trial underpowered to detect modest effects on the primary endpoint. Treatment was limited to 12 months with no post-treatment vitamin C controls, risking informal crossover that may have influenced long-term survival. Baseline imbalances (higher mutational burden and worse prognostic scores in the vitamin C group) could confound exploratory survival results despite multivariable adjustment.

Clinical implications

Oral vitamin C 1000 mg/day appears safe and biologically active in patients with CCUS or lower-risk myeloid malignancies, but it did not reduce clonal growth over 12 months—the survival signal is hypothesis-generating only and should not change current management. A phase 3 trial is needed before routine use can be recommended.

Caveats

  • 57% of participants had deficient or inadequate vitamin C levels at baseline, so results may reflect correction of deficiency rather than a pharmacological effect at replete levels
  • Baseline imbalances favored a higher-risk profile in the vitamin C group (greater mutational burden, worse prognostic scores), which could complicate interpretation of survival differences despite multivariable adjustment
  • Clonal growth rate over 12 months showed minimal change in both arms (~3–5% VAF increase per year), raising questions about its suitability as a surrogate endpoint for treatment efficacy in this population
Show all 4
  • The overall survival benefit is a post hoc exploratory endpoint; the trial was neither powered nor designed to assess survival, so the finding (HR 0.35) should be interpreted as hypothesis-generating only

Related Questions

Explore related topics

Phase 3 vitamin C supplementation myelodysplastic syndromes or CCUS interception trialTET2 mutation clonal hematopoiesis treatment strategies and disease interceptionOral versus intravenous high-dose vitamin C epigenetic effects myeloid malignancies

Publication Details

Year
2026
Journal
Cancer
Sample Size
n=109
Source
View article
Keep scrolling
More content below.
Up Next